Table 1

General data of patients combined with renal TMA and lupus nephritis

No.

Age (years)

Clinical diagnosis

Pathological types

CFH (μg/ml)

ACL

Anti-β2GP-1

ADAMTS-13 Activity (%)

C4d deposition on vascular wall


1

25

LN

IV-G(A/C)

386.0

-

-

88

-

2

38

LN

IV-G(A/C)

670.2

-

-

83

++

3

34

LN

IV-G(A)

166.8

-

-

70

+

4

45

LN+MHT

IV-G(A/C)

694.8

-

-

68

-

5

28

LN

IV-G(A/C)

298.8

-

-

94

+

6

43

LN

IV-G(A)+V

642.8

-

-

75

-

7

26

LN+Scleroderma

IV-G(A)

136.0

-

-

74

+

8

26

LN

IV-G(A)+V

112.8

-

-

95

-

9

23

LN

IV-G(A)+V

385.4

-

-

91

+

10

27

LN+TTP-HUS

IV-G(A/C)

146.0

-

-

97

+

11

32

LN

III(A/C)+V

467.6

-

-

95

+

12

38

LN+MHT

IV-G(A/C)

251.6

-

-

98

-

13

20

LN

IV-G(A)

362.4

-

-

98

-

14

31

LN

IV-G(A)

551.2

-

-

71

-

15

25

LN

IV-G(A)

567.4

-

-

85

+

16

19

LN

IV-G(A)

620.4

-

-

98

+

17

34

LN+TTP-HUS

IV-G(A)

365.6

-

-

89

-

18

19

LN

IV-S(A)

457.0

-

-

89

-

19

31

LN

IV-G(A)

491.4

-

-

97

-

20

18

LN+APS

IV-G(A)+V

162.0

+

-

45

+

21

30

LN+APS

V

707.2

-

+

98

+

22

43

LN

III(A/C)+V

498.8

-

-

96

+

23

24

LN

IV-G(A/C)

222.4

-

-

96

+

24

35

LN

IV-G(A/C)

540.0

-

-

99

-

25

40

LN

IV-G(A/C)

117.8

-

-

98

-

26

21

LN

III

201.2

-

-

63

+

27

38

LN

IV-G(A)

672.6

-

-

88

+

28

52

LN

IV-G(A/C)

131.0

-

-

96

-

29

37

LN

V

340.0

-

-

32

-

30

27

LN

IV-G(A)

124.4

-

-

95

-

31

18

LN

IV-G(A/C)

492.8

-

-

95

-

32

15

LN

IV-G(A)

221.2

-

-

97

++

33

33

LN

IV-G(A)

374.0

-

-

80

+

34

15

LN

IV-G(A)

407.2

-

-

68

+

35

40

LN

V

434.2

-

-

96

-

36

20

LN

IV-G(A)

627.6

-

-

97

+


Note: The normal range of serum CFH was 561.3 ± 179.7 (381.6 to 741.0) μg/ml. The normal range of ADAMTS-13 activity was 95% (42% to 99%). Abbreviations: APS, anti-phospholipid syndrome; LN, lupus nephritis; MHT, malignant hypertension; TTP-HUS, thrombotic thrombocytopenic purpura-hemolytic uremic syndrome

Song et al. Arthritis Research & Therapy 2013 15:R12   doi:10.1186/ar4142

Open Data